ReviewNanomaterials (Basel, Switzerland)2022
Biocompatible Iron Oxide Nanoparticles for Targeted Cancer Gene Therapy: A Review.
Review in Nanomaterials (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 53 citations in OpenAlex.
- Magnetic Hyperthermia via ZnPharmaceutics · 2026Article
- In vitro release kinetics and in vivo plasma exposure of green tea polyphenols and caffeine from iron oxide chitosan nanoparticles.Scientific reports · 2026Article
- Magnetic Field-Driven Strategies for Biofilm Disruption: From Iron Oxide Nanoparticles to Adaptive Swarms of Magnetic Microrobots.ACS nano · 2026Review
- Clinical Applications and Future Prospects of Metallic Nanoparticles in Diagnosis and Therapy.International journal of nanomedicine · 2026Review
- Theranostic Potentials of Metallic Nanoparticles in Thyroid Diseases: Challenges and Prospects.International journal of nanomedicine · 2026Review
- Green-synthesized superparamagnetic and biocompatible FeScientific reports · 2025Article
- Small Interfering RNA Carriers for Oncotherapy: A Preclinical Overview.Pharmaceutics · 2025Review
- Nanoparticle-Based Delivery Systems for Synergistic Therapy in Lung Cancers.Bioengineering (Basel, Switzerland) · 2025Review
- Nanozyme-mediated glutathione depletion for enhanced ROS-based cancer therapies: a comprehensive review.Nanomedicine (London, England) · 2025Review
- Prospects and Challenges of Chitosan-Based Drug Carriers for Anticancer Agents' Delivery Against Lung Cancer: A Review.Drug design, development and therapy · 2025Review
- Recent developments in two-dimensional molybdenum disulfide-based multimodal cancer theranostics.Journal of nanobiotechnology · 2024Review
- Influence of Physicochemical Properties of Iron Oxide Nanoparticles on Their Antibacterial Activity.ACS omega · 2024Review
- Iron Oxide Nanoparticles: Parameters for Optimized Photoconversion Efficiency in Synergistic Cancer Treatment.Journal of functional biomaterials · 2024Review
- The Recent Applications of Magnetic Nanoparticles in Biomedical Fields.Materials (Basel, Switzerland) · 2024Review
- SPIONs: Superparamagnetic iron oxide-based nanoparticles for the delivery of microRNAi-therapeutics in cancer.Biomedical microdevices · 2024Review
- Synergistic Immunoregulation: harnessing CircRNAs and PiRNAs to Amplify PD-1/PD-L1 Inhibition Therapy.International journal of nanomedicine · 2024Review
- Iron oxide-coupled CRISPR-nCas9-based genome editing assessment in mucopolysaccharidosis IVA mice.Molecular therapy. Methods & clinical development · 2023Article
- Review
- Iron Oxide Nanoparticles in Cancer Treatment: Cell Responses and the Potency to Improve Radiosensitivity.Pharmaceutics · 2023Review
- Inorganic nanoparticle-integrated mesenchymal stem cells: A potential biological agent for multifaceted applications.MedComm · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
In recent years, gene therapy has made remarkable achievements in tumor treatment. In a successfully cancer gene therapy, a smart gene delivery system is necessary for both protecting the therapeutic genes in circulation and enabling high gene expression in tumor sites. Magnetic iron oxide nanoparticles (IONPs) have demonstrated their bright promise for highly efficient gene delivery target to tumor tissues, partly due to their good biocompatibility, magnetic responsiveness, and extensive functional surface modification. In this review, the latest progress in targeting cancer gene therapy is introduced, and the unique properties of IONPs contributing to the efficient delivery of therapeutic genes are summarized with detailed examples. Furthermore, the diagnosis potentials and synergistic tumor treatment capacity of IONPs are highlighted. In addition, aiming at potential risks during the gene delivery process, several strategies to improve the efficiency or reduce the potential risks of using IONPs for cancer gene therapy are introduced and addressed. The strategies and applications summarized in this review provide a general understanding for the potential applications of IONPs in cancer gene therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.